Navigation Links
Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
Date:6/11/2012

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced results from two Phase II studies of their investigational novel basal insulin analog, LY2605541. Results of the type 1 diabetes study showed that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than insulin glargine.  In the type 2 diabetes study, the primary measure showed that LY2605541 and insulin glargine had similar improvements in glycemic control. These data and additional measures from the studies will be presented at the 72nd American Diabetes Association (ADA) Scientific Sessions® in Philadelphia, June 8-12, 2012.

"As a clinical investigator, these Phase II results are intriguing, as they showed that LY2605541 improved glycemic control in patients with type 1 and type 2 diabetes and produced additional effects, such as weight loss and less variability of blood glucose readings, both within the same day and between days," said Richard Bergenstal, MD, executive director, International Diabetes Center at Park Nicollet and clinical professor, Department of Medicine, University of Minnesota.

"Lilly and Boehringer Ingelheim are excited to have the opportunity to share both the pre-clinical and clinical study data completed to date for LY2605541, and are pleased that these Phase II study results support the continued clinical development of this basal insulin," said David Kendall, MD, distinguished medical fellow, Lilly Diabetes. "Based on the  pre-clinical studies completed, compared to injected human insulin, LY2605541 appeared to work preferentially in the liver, which is more like the body's own insulin. We look forward to results from our ongoing Phase III clinical trials."

Glycemic Control
In adults with type 1 diabetes, patients treated with LY2605541 showe
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
11. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... membrane market has witnessed robust development with the growth pace ... later starter. In 2012, the size of China ... the proportion worldwide soaring to 16.3%. It is projected that ... its growth rate by around 20% in the upcoming years ... RMB25 billion. An integrated membrane industrial system has ...
(Date:12/17/2014)... 2014  Northstar Global Business Services, Inc. (OTCPink:MDIN) ... has made their final decision and has determined ... stock effective December 15, 2014, and has resumed ... and book entry transfer services. All deposit restrictions have ... again fully "DTC Eligible", and has resumed electronic ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... 16, 2011 PDL BioPharma, Inc. (PDL) (NASDAQ: ... 15, 2011, regular quarterly dividend payment of $0.15 per share to ... the record date. About PDL BioPharma ... by doing so, enabled the discovery of a new generation of ...
... 2011 The U.S. Food and Drug Administration today ... adult patients who have had a kidney transplant. ... immunosuppressants (medications that suppress the immune system) -- ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Nulojix is ...
Cached Medicine Technology:FDA Approves Nulojix for Kidney Transplant Patients 2FDA Approves Nulojix for Kidney Transplant Patients 3
(Date:12/21/2014)... (PRWEB) December 22, 2014 Weddingshe.com, an ... occasion gowns, has recently released its new selection of ... models are made according to the newest fashion trends. ... stunning dresses for cocktail parties . All of ... 80 percent off. We are making every effort to ...
(Date:12/21/2014)... December 21, 2014 Khanna Vision Institute ... guest at the Aspen Helicopters holiday event for underprivileged ... Santa with sleigh, flown by an aspen helicopter pilot. ... only Santa with sleigh was visible.(please see accompanying video). ... night. Dr.Khanna has helped many pilots with Pi in ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding dresses ... new designs in this collection, and all of them ... AngelWeddingDress.com promises to provide the most fashionable designs ... many fashion trends come and go. If ladies have ... AngelWeddingDress.com is ready to assist. , “These new ...
(Date:12/21/2014)... Dennis Thompson HealthDay Reporter ... smokers find e-cigarettes less addictive than traditional cigarettes, new research ... as they did regular cigarettes, thousands of ex-smokers said they ... and irritable over their need to smoke, researchers reported. ... was significantly less for e-cig use than for tobacco use," ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
Breaking Medicine News(10 mins):Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3
... International Diabetes Federation (IDF) BRIDGES translational research grant ... seeks to reduce the risk of for people ... The community based diabetes prevention programme will determine ... research studies of lifestyle interventions for diabetes prevention ...
... YORK (May 29, 2008) -- Physician-scientists from NewYork-Presbyterian ... research findings at the American Society of Clinical ... June 3. Among the most significant presentations are ... OncoVEXGM-CSF for Patients With Unresectable Metastatic Melanoma , ...
... N.J., May 30 Lutronic, Inc., one of,the ... systems,announced today that its MOSAIC eCO2 system, the ... with the deep,ablative features of a CO2 laser, ... and,clearance., With intuitive touch-screen software, the powerful ...
... The world was stunned by the,news of ... 70,000 dead and,thousands more injured and homeless. In ... Wheelchair Mission (FWM), a non-profit,organization dedicated to transforming ... with Holistic Integrated Service Foundation (HIS),a nonprofit in ...
... Find New Video ,Milestones in Oncology, Presentations at ... The Society for Translational Oncology,(STO) is pleased to ... uniquely valuable video presentations for practicing,oncologists., (Logo: ... made on the occasion of the 2008 Annual ...
... with advanced cancer were more likely than whites to ... greater preference among blacks for life-extending treatment even in ... study led by researchers at Dana-Farber Cancer Institute in ... the annual meeting of the American Society of Clinical ...
Cached Medicine News:Health News:International Diabetes Federation grant supports study to prevent type 2 diabetes in India 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 3Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 4Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Free Wheelchair Mission to Distribute 4,400 Wheelchairs to China Earthquake Victims 2Health News:Society for Translational Oncology Launches Updated Website 2Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2
... is the first truely web-based solution on the ... POC (managed from the lab) and Critical Care ... of AegisPOC ensures that all groups have the ... in the manner best suited to them. Through ...
... ultrasonic technology. When managing glaucoma patients and ... to use the best technology available. ... analog and digital technology that utilizes ultrasound ... other ultrasonic pachymeters in the market. This ...
...
...
Medicine Products: